| Albert Nalli Dpm Inc | |
|
510 Maplewood Ave, Ambridge, PA 15003-2412 | |
| (724) 266-3180 | |
| (724) 266-1740 |
| Full Name | Albert Nalli Dpm Inc |
|---|---|
| Type | Facility |
| Speciality | Podiatrist |
| Location | 510 Maplewood Ave, Ambridge, Pennsylvania |
| Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1396926556 | NPI | - | NPPES |
| 1563791 | Other | PA | HIGHMARK BCBS |
| 1008690830001 | Medicaid | PA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213E00000X | Podiatrist | SC001753L (Pennsylvania) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Albert Nalli Dpm Inc 510 Maplewood Ave, Ambridge, PA 15003-2412 Ph: (724) 266-3180 | Albert Nalli Dpm Inc 510 Maplewood Ave, Ambridge, PA 15003-2412 Ph: (724) 266-3180 |
News Archive
Arena Pharmaceuticals, Inc. announced today Merck and Co., Inc.'s decision (through an affiliate) to discontinue development of MK-1903, an investigational niacin receptor agonist to treat atherosclerosis being developed under its research collaboration with Arena. Merck also informed Arena that the company will not continue the collaboration.
Coupling free diagnostic tests for malaria with discounts on artemisinin combination therapy (ACT) when malaria is diagnosed can improve the rational use of ACTs and boost testing rates, according to a cluster-randomized trial published this week in PLOS Medicine by Wendy Prudhomme O'Meara of Duke University, USA, and colleagues.
A team of researchers from the University of Maryland School of Pharmacy and the University of Maryland School of Medicine found that current (prolonged) use of serotonin reuptake inhibitors – a major class of antidepressant medications – in children and adolescents was associated with a nearly two-fold increased risk of developing type 2 diabetes when compared to youths who formerly used (but eventually discontinued) those medications.
According to a recent study, there is a new mechanism of drug release using 3D superhydrophobic materials that utilizes air as a removable barrier to control the rate at which drug is released.
ChromaDex Corp. and the University of Mississippi today announced the university has granted the natural products company the exclusive worldwide patent rights to a potential new therapeutic use for pterostilbene (tero-STILL-bean) as an anxiolytic or anti-anxiety agent. ChromaDex' pTeroPure® is an ultra-pure formulation of pterostilbene, a compound found in blueberries and demonstrated to have multiple health benefits.
› Verified 8 days ago
Dr. Tad Justin Borland, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 510 Maplewood Ave, Ambridge, PA 15003 Phone: 724-266-3180 | |
Step Right Podiatry, Inc Podiatrist Medicare: Medicare Enrolled Practice Location: 510 Maplewood Ave, Ambridge, PA 15003 Phone: 724-266-3180 Fax: 724-266-1740 | |
Ambridge Podiatry Associates Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 447 Maplewood Ave, Ambridge, PA 15003 Phone: 724-266-1867 | |
Dr. Albert R Nalli, DPM Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 510 Maplewood Ave, Ambridge, PA 15003 Phone: 724-266-3180 Fax: 724-266-1740 |